Can a lipid cream stop healed wounds from reopening?

NCT ID NCT02577120

Ongoing Disease control Sponsor: Sashwati Roy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special lipid cream (EpiCeram) can prevent healed chronic wounds—like diabetic foot ulcers or pressure sores—from reopening. About 100 adults with recently healed wounds will apply either the cream or Vaseline for 3 months. Researchers will measure skin barrier function to see if the cream helps wounds stay closed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EpiCeram (lipid-rich cream) and Vaseline (petroleum jelly)
What this could lead to: If successful, this could point toward a simple cream to reduce the chance that a healed chronic wound reopens.
What could go wrong: This is an early-phase study with a small number of participants, so results may not apply broadly. The cream is compared to Vaseline, and the main measure (TEWL) is a skin function test, not a direct clinical outcome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BURN WOUND are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome burn chronic ulcer of skin decubitus ulcer Diabetic Foot injury ulcer of lower limbs

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BURN WOUND CHRONIC CHRONIC WOUND DIABETIC FOOT ULCERS PRESSURE ULCERS VENOUS LEG ULCERS WOUND

Contacts and locations

Locations

University of Pittsburgh / McKeesport Clinic

Pittsburgh, Pennsylvania, 15132, United States
University of Pittsburgh / Mercy Clinic

Pittsburgh, Pennsylvania, 15219, United States
University of Pittsburgh / Passavant

Pittsburgh, Pennsylvania, 16066, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.